Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.
Jpn J Pharmacol
; 84(3): 351-4, 2000 Nov.
Article
en En
| MEDLINE
| ID: mdl-11138738
ABSTRACT
We investigated the effects of T-1095 (3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl)-beta-D-glucopyranoside), an orally active inhibitor of Na+-glucose cotransporter, on hyperglycemia and insulin resistance in skeletal muscle of streptozotocin (STZ)-induced diabetic rats. Chronic (4 weeks) administration of T-1095 as food admixture (0.01 -0.1% wt/wt) suppressed the blood glucose level without affecting the food intake and body weight. In addition, the reduced 2-deoxyglucose uptake and lactate release in the soleus muscle of STZ rat was ameliorated by chronic treatment of T-1095. These data suggest that T-1095 improves insulin sensitivity in skeletal muscle through correction of hyperglycemia and has novel therapeutic potential for treatment of diabetes mellitus through removing glucose toxicity.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proteínas de Transporte de Monosacáridos
/
Resistencia a la Insulina
/
Carbonatos
/
Diabetes Mellitus Experimental
/
Glucósidos
/
Hiperglucemia
/
Hipoglucemiantes
Tipo de estudio:
Diagnostic_studies
Límite:
Animals
Idioma:
En
Revista:
Jpn J Pharmacol
Año:
2000
Tipo del documento:
Article
País de afiliación:
Japón